Open AccessEvaluation of silodosin in comparison to tamsulosin in benign prostatic hyperplasia: A randomized controlled trial
Author(s) -
Satabdi Pande,
Avijit Hazra,
Anup Kumar Kundu
Publication year - 2014
Publication title -
indian journal of pharmacology/the indian journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.286
H-Index - 59
eISSN - 1998-3751
pISSN - 0253-7613
DOI - 10.4103/0253-7613.144912
Subject(s) - silodosin , tamsulosin , medicine , international prostate symptom score , urology , lower urinary tract symptoms , sexual function , randomized controlled trial , adverse effect , ambulatory , prostate , hyperplasia , cancer
Benign prostatic hyperplasia (BPH) is the most common cause of lower urinary tract symptoms in elderly men. Selective alfa1-adrenergic antagonists are now first-line drugs in the medical management of BPH. We conducted a single-blind, parallel group, randomized, controlled trial to compare the effectiveness and safety of the new alfa1-blocker silodosin versus the established drug tamsulosin in symptomatic BPH.